Breaking News
The U.S. Food and Drug Administration (FDA) has approved a new type of antibiotic to treat urinary tract infections (UTIs).
Specific lots of intravenous immune globulin (IVIG) and subcutaneous IG (SCIG) have been voluntarily withdrawn by the manufacturers due to a higher rate of allergic/hypersensitivity type reactions, some of which were considered medically significant.
Grifols announced positive results from its Phase II/III clinical trial evaluating the efficacy and safety of Flebogamma 5% DIF (intravenous immune globulin [IVIG]) to treat patients with post-polio syndrome, which demonstrated a significant improvement in distance walked compared to placebo.
BioTrending
- By Trudie Mitschang
When it comes to online health information, the Internet is a place where falsehoods flourish. Combating questionable content is no easy task, requiring education, legislation and diligence from stakeholders in the healthcare, scientific and public health communities.
- By Meredith Whitmore
Your words, tone and body language can escalate patient fears, but they also have the power to ease anxiety and help patients cope.
- By Jim Trageser
Though mostly eradicated in the U.S., treatment for rabies must begin immediately with hyperimmune globulin and vaccines.
- By Keith Berman, MPH, MBA
With 16 FVIII products now approved for the treatment of hemophilia A, many patients with this disease are now able to live a normal life.
BSTQ Podcast: Marketplace News & Insights
Awards
BSTQ is an Industry Award-Winning Journal
Since its debut in 2009, BioSupply Trends Quarterly’s articles have been recognized by some of the industry’s most prominent organizations, earning platinum and gold awards.
